Slide 1: IRIDEX Corporation Singular Research Conference
IRIDEX Corporation Singular Research Conference – San Francisco, CA NASDAQ: IRIX June 9, 2016 Exhibit 99.1
Slide 2: Safe Harbor
Safe Harbor Participation in this presentation requires that you be aware of the Federal legislation regarding forward-looking statements. Accordingly, during the course of this presentation we may make forward-looking statements regarding future events or the future performance of the Company. We c
Slide 3: Future Growth and Revenue: Business Priorities
IRIDEX Corporation Future Growth and Revenue New Business Model New Technologies New Growth Trajectory Business Priorities
Slide 4: Our Business: Retinal Disease and Glaucoma Treatments
Our Business: Retinal Disease and Glaucoma Treatments Glaucoma Business Retina Business
Slide 5: Macro Trends Driving MicroPulse Demand
Macro Trends Driving MicroPulse® Demand people with glaucoma, 17 million diagnosed 65M Growing Elderly Populations people worldwide with age-related, vision-threatening retinal disease by 2021 343M Additional retinal indications High cost and sustainability of pharmacotherapy + +
Slide 6: Value-Based Medicine
® Value-Based Medicine IRIDEX Photostimulation Laser Pharma Tradewinds Increased patient pop. Favorable economics 4 Tanah canes Ease of injections www IRIDEX.com
Slide 7: Transitioning to High Growth
Transitioning to High Growth An Evolving Business to Compelling New Opportunities Legacy Premium Proprietary Scalable Platform Razor/Razorblade
Slide 8: Compelling Clinical Advancements: Retina Business
| Compelling Clinical Advancements Retina Business
Slide 9: Problem and Solution
Problem and Solution Traditional vs. Mircropulse graphic from scarring to non-scarring Traditional Pre-treatment 1 Year Post-treatment Pre-treatment 1 Year Post-treatment Scarring non-existent with equivalent visual acuity results as traditional laser, plus increased retinal sensitivity, using Micro
Slide 10: Clinical Evidence: Safety, Efficacy, Efficiency, Economics
Clinical Evidence Safety Efficacy Efficiency Economics 10-year follow-up data proved no detectable retina damage. Control randomized trials showed improved vision and improved retinal sensitivity. More treatable patients. Improved patient pass-through rates. IQ 577™ and TxCell™ nearly paid for itsel
Slide 11: Targeted Market Segment: Retina Market
Targeted Market Segment Understanding Retina Market breakdown and opportunity Historical Market predominantly replacement opportunity New Market MicroPulse laser for retinal treatment
Slide 12: New Solutions Across the Glaucoma Spectrum
New Solutions Across the Glaucoma Spectrum Glaucoma Business
Slide 13: Glaucoma Global Macro Trends
Glaucoma Global Macro Trends Estimated 65 million patients worldwide, 17 m diagnosed Aging population demographic - 50% of glaucoma patients are above 70 Compliance is the issue - 50% of patients stop taking meds at 1 year 65M 70+ 50%
Slide 14: Glaucoma Market Segmentation
Glaucoma Market Segmentation |$5.5B spent on Medications
Slide 15: Targeted Market Segment: $2B Opportunity
# Treatments/year* 2 Average Probe Price $200 Number of Patients 5 M TAM $2 B 10.4M Patients Worldwide on Meds 5M Patients Worldwide on Multiple Meds Targeted Market Segment: 5M Patients on Multiple Glaucoma Meds Represent $2B Opportunity
Slide 16: Data from the Focused US Rollout
Data from the Focused US Rollout Future Growth and Revenue $20 K Recurring Probe Sales Placements Opportunity x = 300 ASCs control 50% of glaucoma surgical volume [of which 47 are IRIDEX customers] 5,000 ASCs perform eye surgery 19,000 Ophthalmologists
Slide 17: Cyclo G6: The New Solution
Cyclo G6: The New Solution Innovative Glaucoma System Provides Competitive Advantage MicroPulse® P3 G-ProbeTM Cyclo G6TM Laser Console Intelligence resides in the probe, not the appliance Revolutionary strategy and technology provide inherent competitive advantage Growing portfolio allows treatment
Slide 18: Expanding Probe Portfolio to Grow Procedural Opportunity
Expanding Probe Portfolio to Grow Procedural Opportunity Drugs Trabeculoplasty MIGS Traditional Surgery MicroPulse P3 G-ProbeTM Early to Mid-stage Late stage Four Probes under Development
Slide 19: Cyclo G6: Immediate Commercial Impact
Cyclo G6: Immediate Commercial Impact G6 Console Units Cyclo G6 Probe Revenue 2015Q1 March Launch G6 Laser Console and G6 Probe sales since launch 2015Q4 2015Q3 2015Q2 2016Q1 9 15 21 68 74 0 10 20 30 40 50 60 70 80 2015Q1 March Launch 2015Q4 2015Q3 2015Q2 2016Q1 $81,000 $- $100,000 $200,000 $300,000
Slide 20: Global Cyclo G6 Data
Global Cyclo G6 Data as of June 1, 2016 Worldwide G6 units sold (75% in the US) 261 Total G6 probes shipped since March 2015 launch 17,172 Total G6 probes shipped in 2016 9,579 Countries have purchased 20
Slide 21: Clinical Evidence: Cyclo G6 Studies
Clinical Evidence NUHS Prospective Clinical Study Studies in Progress Wills Eye: Retrospective study shows 39% IOP reduction Ongoing prospective study reporting 54% IOP reduction at three months UC San Francisco studied anatomical effects – reporting high safety profile Yale University study demonst
Slide 22: Focusing on the Vision
>cuting on the Vision RIDEX.com
Slide 23: Commercial Models
Commercial Models Separate Models | Different Markets Legacy Hardware Legacy Consumables G6 Platform
Slide 24: Financial Snapshot: Q1 2016
Financial Snapshot Most Recent Quarterly Results – Q1, 2016 P&L Balance Sheet 2016 Guidance: Double-digit growth, accelerating in second half Cash $10.5 MM Debt $0.00 Revenue $11.9M Growth Rate from Q1 FY15 11%
Slide 25: Additional Financial Information
Additional Financial Information ]Q1 CAGR ~44%
Slide 26: Business Model Targets
Business Model Targets 60% consumable, 40% equipment 50/50 retina and glaucoma 40/60 US and International 55+% gross margin, 15+% operating margin
Slide 27: Future Growth and Revenue
IRIDEX Corp. Future Growth and Revenue New Technologies New Business Model New Growth Trajectory
Slide 28: References
References Slide 5: Global estimates of diabetes prevalence for 2013 and projections for 2035,” International Diabetes Foundation, Diabetes Research and Clinical Practice, 2014;103:137-149. Market Scope 2015 Comprehensive Global Report Slide 6: Market Scope 2015 Comprehensive Global Report Slide 9:
Slide 29: Thank you
thank you.
Slide 30: Clinical Resources
Clinical Resources Financials Resources Video Saksonov, Poster MicroPulse 577 Cystoid ME due to BRVO, APVRS 2011 Mahootchi, Rethinking Regimen for Retina Disease, RT 2014 Saksonov, MicroPusle 577 vs Classic ME due to BRVO AVPRS-VRSI 2011 Gossage, 532 TxCell MicroPulse ME due to BRVO, RT 2014 Inagaki
Slide 31: Video Resources
Video Resources Financials Resources Video Video 1: MicroPulse Technology Animation Video 2: Cyclo G6 Laser System Technology Video 3: Transscleral Cyclophotocoagulation with Cyclo G6 Video 4: Interview with Dr. Jacky Lee at ESCRS 2015 Video 5: Media Release on New Treatments for Glaucoma (Chinese w